BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2960532)

  • 1. Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients.
    Gasparini G; Canobbio L; Galligioni E; Fassio T; Brema F; Crivellari D; Villalta D; Di Fronzo G; Talamini R; Monfardini S
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1451-9. PubMed ID: 2960532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S; Yamamoto H; Inaii H; Koyama H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M; Alonso MC; Ojeda MB; Izquierdo A; Ferrer J; Picó C; Anglada L; Catalán G; Batiste-Alentorn E; Tusquets I
    Ann Oncol; 1991 Jul; 2(7):495-9. PubMed ID: 1832944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
    Pannuti F; Martoni A; Farabegoli G; Piana E
    Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
    De Lena M; Tommasi S; Schittulli F; Lorusso V; Paradiso A
    Tumori; 1990 Apr; 76(2):190-5. PubMed ID: 2139523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
    Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
    J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
    Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
    Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects.
    Canobbio L; Galligioni E; Gasparini G; Fassio T; Crivellari D; Villalta D; Santini G; Monfardini S; Boccardo F
    Breast Cancer Res Treat; 1987 Nov; 10(2):201-4. PubMed ID: 3427228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P; Alonso MC; Avella A; Beltrán M; Borrás J; Ojeda B; Bosch FX
    Cancer; 1985 Dec; 56(12):2745-50. PubMed ID: 3902200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
    Pannuti F; Martoni A; Cilenti G; Camaggi CM; Fruet F
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):423-9. PubMed ID: 2968262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.
    Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt JL; Rose C
    Cancer Treat Rep; 1979 Feb; 63(2):171-5. PubMed ID: 376131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
    van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
    Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
    Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
    Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL
    Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Am J Clin Oncol; 1988 Aug; 11(4):431-4. PubMed ID: 2970218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.